Two medical device firms have signed a deal aimed at taking a cutting edge anaesthesia device – which was developed with the help of UK clinicians – into 60 countries.
Medovate and Vygon Group have announced an exclusive deal to distribute SAFIRA (SAFer Injection for Regional Anaesthesia) globally.
Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.
The device was developed in collaboration with the NHS. It transforms the technique of Peripheral Nerve Blockade into a one-person procedure, giving the anaesthetist full control of the injection at all times.
The technology also “improves patient safety by helping reduce the risk of nerve damage, as it prevents anaesthetic from being injected at high pressures”. Furthermore, economic modelling has shown SAFIRA has the potential to help generate significant time and cost savings in a medical setting, the companies say.
During the coronavirus crisis, the European Society for Regional Anaesthesia (ESRA) has recommended that regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient.
Regional anaesthesia preserves respiratory function and avoids aerosolisation and the potential for transmission of COVID-19, compared to general anaesthesia. By making regional anaesthesia a one-person procedure SAFIRA helps hospitals meet these recent recommendations.
Vygon is one of the largest independent French medical device companies. It supplies more than 205 million products globally per year and is a world-leader in regional anaesthesia.
Medovate is a medtech company that develops new technologies created through its development pipeline of NHS innovations, with a focus on anaesthesia, airway, critical care and surgery.
Stuart Thomson, managing director of Medovate, says: “This agreement with Vygon marks a significant milestone in the launch of SAFIRA across Europe, the US and a number of other markets,” said Stuart Thomson, Managing Director, Medovate.
“This will help establish Medovate on the world stage as a recognized medical device developer and manufacturer. In addition, it raises the international profile of the UK NHS and its clinicians, who are key stakeholders in Medovate and inventors of the SAFIRA innovation.”
John Kerridge, vice president, anaesthesia and emergency business unit, Vygon, says: “This is a very exciting partnership for Vygon. The SAFIRA technology, in terms of its impact on patient safety and clinical end-user efficiency, is in-line with our overall objective of patient/practitioner-based healthcare solutions. The fact that in the very near future the SAFIRA technology will be available in NRFit format further supports this objective. It will enable us to offer a complete NRFit solution for those markets that demand it.”
It is estimated that ten million regional anaesthesia procedures are performed across Europe every year.